JP2003529540A - 癌細胞死および腫瘍後退を誘導する方法 - Google Patents

癌細胞死および腫瘍後退を誘導する方法

Info

Publication number
JP2003529540A
JP2003529540A JP2000610478A JP2000610478A JP2003529540A JP 2003529540 A JP2003529540 A JP 2003529540A JP 2000610478 A JP2000610478 A JP 2000610478A JP 2000610478 A JP2000610478 A JP 2000610478A JP 2003529540 A JP2003529540 A JP 2003529540A
Authority
JP
Japan
Prior art keywords
inhibitor
signaling pathway
ras signaling
cancer
fpt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000610478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529540A5 (https=
Inventor
ウォルター アール． ビショップ，
ダイアナ エル． ブラッサード，
タッタナーリ エル． ナガブシャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2003529540A publication Critical patent/JP2003529540A/ja
Publication of JP2003529540A5 publication Critical patent/JP2003529540A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000610478A 1999-04-09 2000-04-06 癌細胞死および腫瘍後退を誘導する方法 Pending JP2003529540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/289,255 US6316462B1 (en) 1999-04-09 1999-04-09 Methods of inducing cancer cell death and tumor regression
US09/289,255 1999-04-09
PCT/US2000/009124 WO2000061145A1 (en) 1999-04-09 2000-04-06 Methods of inducing cancer cell death and tumor regression

Publications (2)

Publication Number Publication Date
JP2003529540A true JP2003529540A (ja) 2003-10-07
JP2003529540A5 JP2003529540A5 (https=) 2007-05-24

Family

ID=23110723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610478A Pending JP2003529540A (ja) 1999-04-09 2000-04-06 癌細胞死および腫瘍後退を誘導する方法

Country Status (24)

Country Link
US (1) US6316462B1 (https=)
EP (1) EP1165078B1 (https=)
JP (1) JP2003529540A (https=)
CN (1) CN100421661C (https=)
AR (1) AR023400A1 (https=)
AT (1) ATE347360T1 (https=)
AU (1) AU783177B2 (https=)
BR (1) BR0009670A (https=)
CA (1) CA2364675A1 (https=)
CY (1) CY1107545T1 (https=)
DE (1) DE60032226T2 (https=)
DK (1) DK1165078T3 (https=)
ES (1) ES2275505T3 (https=)
HK (1) HK1038512B (https=)
HU (1) HUP0200773A3 (https=)
MX (1) MXPA01010211A (https=)
MY (1) MY120841A (https=)
NO (1) NO329133B1 (https=)
NZ (1) NZ514628A (https=)
PE (1) PE20010025A1 (https=)
PT (1) PT1165078E (https=)
TW (1) TWI255184B (https=)
WO (1) WO2000061145A1 (https=)
ZA (1) ZA200108258B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CA2376596C (en) * 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2424797C (en) 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
CN101220033A (zh) * 2001-01-18 2008-07-16 先灵公司 替莫唑胺和类似物的合成
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
AU2003287366A1 (en) * 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
EP2283831A3 (en) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
JP5198289B2 (ja) * 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
US20100112039A1 (en) * 2006-10-25 2010-05-06 Schering Corporation Methods of treating ovarian cancer
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
EP2409700A1 (en) 2007-05-08 2012-01-25 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
WO2009145852A1 (en) * 2008-04-17 2009-12-03 Concert Pharmaceuticals, Inc. Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
RU2014126098A (ru) 2011-11-30 2016-01-27 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US11331312B2 (en) * 2014-04-25 2022-05-17 Memorial Sloan-Kettering Cancer Center Treatment of H-Ras-driven tumors
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CA3151110A1 (en) 2019-08-16 2021-02-25 Children's Hospital Medical Center Methods of treating a subject with a cdc42-specific inhibitor
PL4426303T3 (pl) 2021-11-02 2026-02-09 Semmelweis Egyetem Inhibitory transferazy farnezylowej i inhibitory kras do leczenia nowotworów z mutacją kras
CN120053663B (zh) * 2024-04-15 2025-12-12 天津医科大学 Sp/klf转录因子抑制剂与去乙酰化酶抑制剂组合的制药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0411048A1 (en) 1988-04-28 1991-02-06 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
NZ251540A (en) 1992-03-27 1996-09-25 Schering Corp Bridged bis-aryl carbinol derivatives, preparation and medicaments
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
FR2698560B1 (fr) 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
SG48750A1 (en) 1993-10-15 1998-05-18 Schering Corp Tricyclic carbonate compounds useful for inhabition of g-protein function for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5464840A (en) 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
DE69531957T2 (de) 1994-12-19 2004-08-12 Daiichi Pharmaceutical Co., Ltd. Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1997005902A1 (fr) 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
SK86198A3 (en) 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
CA2251716A1 (en) 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
EP0952842A2 (en) 1996-04-18 1999-11-03 Merck & Co., Inc. A method of treating cancer
DE69730241T2 (de) 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5965570A (en) 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
US5985879A (en) 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
SK33699A3 (en) 1996-09-13 2000-03-13 Schering Corp Tricyclic compounds useful for inhibition of farnesyl protein transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5861395A (en) 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US5958890A (en) 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
CZ298488B6 (cs) 1997-02-18 2007-10-17 Canji, Inc. Farmaceutický prostredek s obsahem tumor-supresorové nukleové kyseliny
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US5939416A (en) 1997-06-17 1999-08-17 Schering Corporation Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5925639A (en) 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5852034A (en) 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5958940A (en) 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
KR100597331B1 (ko) 1997-12-22 2006-07-10 쉐링 코포레이션 생체 이용률이 향상된 분자 분산액 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAVATA,M.F. ET AL, IDENTIFICATION OF A NOVEL INHIBITOR OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE, J, JPN6010044283, ISSN: 0001693031 *
LIU,M. ET AL, ANTITUMOR ACTIVITY OF SCH 66336, AN ORALLY BIOAVAILABLE TRICYCLIC INHIBITOR OF FARNESY, JPN6010044279, ISSN: 0001693030 *
PARRIZAS,M. ET AL, INSULIN-LIKE GROWTH FACTOR 1 INHIBITS APOPTOSIS USING THE PHOSPHATIDYLINOSITOL 3', JPN6010044285, ISSN: 0001693032 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法

Also Published As

Publication number Publication date
ES2275505T3 (es) 2007-06-16
HK1038512A1 (en) 2002-03-22
DE60032226T2 (de) 2007-10-11
PT1165078E (pt) 2007-02-28
PE20010025A1 (es) 2001-02-05
EP1165078B1 (en) 2006-12-06
CY1107545T1 (el) 2013-03-13
NO20014897D0 (no) 2001-10-08
NO20014897L (no) 2001-12-10
EP1165078A1 (en) 2002-01-02
HK1038512B (en) 2007-04-27
CA2364675A1 (en) 2000-10-19
HUP0200773A3 (en) 2003-04-28
WO2000061145A1 (en) 2000-10-19
CN1364084A (zh) 2002-08-14
ZA200108258B (en) 2003-03-26
DK1165078T3 (da) 2007-04-16
CN100421661C (zh) 2008-10-01
MXPA01010211A (es) 2002-09-18
ATE347360T1 (de) 2006-12-15
NO329133B1 (no) 2010-08-30
DE60032226D1 (de) 2007-01-18
HUP0200773A2 (hu) 2002-07-29
BR0009670A (pt) 2002-01-15
TWI255184B (en) 2006-05-21
US6316462B1 (en) 2001-11-13
AR023400A1 (es) 2002-09-04
NZ514628A (en) 2004-01-30
AU4204100A (en) 2000-11-14
AU783177B2 (en) 2005-09-29
MY120841A (en) 2005-11-30

Similar Documents

Publication Publication Date Title
JP2003529540A (ja) 癌細胞死および腫瘍後退を誘導する方法
JP5110756B2 (ja) 癌を処置するための相乗方法および組成物
AU2002211862B2 (en) Methods of inducing cancer cell death and tumor regression
US20070009593A1 (en) Methods of treating cancer
CN101918420A (zh) 癌症治疗方法
WO2006002119A2 (en) Kinase inhibitors for treating cancers
JP2017122085A (ja) 癌からの転移を阻害する方法
EP2694073B1 (en) Combinations of akt and mek inhibitors for treating cancer
CN106659716A (zh) 阿吡莫德组合物及其使用方法
WO2017024032A2 (en) Compositions and methods for treating cancers associated with etbr activation
IL233986A (en) History of diaminopyrimidine, their preparation and their pharmaceutical preparations
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
Młynarczuk-Biały et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells
JP2025503606A (ja) Ｍｅｋ免疫腫瘍学阻害剤及びそれらの治療的使用
CN118159534A (zh) 抑制PI3K同工型α的化合物和用于治疗癌症的方法
JP2001526224A (ja) 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ
Levitzki Protein tyrosine kinase inhibitors as therapeutic agents
US20070270455A1 (en) INHIBITION OF NF-kB
AU2005248948A1 (en) Methods of inducing cancer cell death and tumor regression
HK40029376A (en) Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits
Tseng PDK-1/AKT pathway as targets for chemosensitizing effects
Shelly et al. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110302